RxDoctor Payments Data

Emmanuel Mompi, MD

Gastroenterology · Tampa, FLNPI 1124099742

Payments from drug & device makers

$8,823in general payments, 2019–2025

Across 229 payments — averaging $38.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$813
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$576
  • Janssen Scientific Affairs, LLC$502
  • Intercept Pharmaceuticals, Inc.$430
  • Braintree Laboratories, Inc.$357
  • plus $3K from 24 others

What the payments were for

  • Food & beverage$8,53797%
  • Education$260%
  • Gifts$2603%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,823 in reported general payments places this provider in the 70th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$30,711
Medicare patients
99
Services billed
228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab11$174,831
LinzessLinaclotide112$119,793
IbsrelaTenapanor Hcl19$36,494
Sucralfate122$14,207
MotegrityPrucalopride Succinate11$5,875
Dicyclomine Hcl86$2,427
Pantoprazole Sodium163$1,318
Clarithromycin27$1,030
Omeprazole88$1,023
Esomeprazole Magnesium23$969
Famotidine48$601
Ondansetron OdtOndansetron19$337
Amoxicillin27$163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$3,040$119,793112 claims
Ardelyx, Inc.Ibsrela$144$36,49419 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$191$5,87511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →